{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T23:52:33Z","timestamp":1788997953003,"version":"build-2803163510"},"reference-count":153,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["4R00AI138586"],"award-info":[{"award-number":["4R00AI138586"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100021041","name":"American College of Allergy Asthma & Immunology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100021041","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["annallergy.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Allergy, Asthma & Immunology"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.anai.2025.06.032","type":"journal-article","created":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T03:16:03Z","timestamp":1751426163000},"page":"466-477","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Management of indolent mastocytosis and mast cell activation syndrome"],"prefix":"10.1016","volume":"135","author":[{"given":"Cem","family":"Akin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph H.","family":"Butterfield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariana","family":"Castells","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan J.","family":"Lyons","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.anai.2025.06.032_bib0001","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1159\/000328760","article-title":"Definitions, criteria and global classification of mast cell disorders with special reference to mast cell activation syndromes: a consensus proposal","volume":"157","author":"Valent","year":"2012","journal-title":"Int Arch Allergy Immunol"},{"issue":"7","key":"10.1016\/j.anai.2025.06.032_bib0002","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/S0145-2126(01)00038-8","article-title":"Diagnostic criteria and classification of mastocytosis: a consensus proposal","volume":"25","author":"Valent","year":"2001","journal-title":"Leuk Res"},{"issue":"12","key":"10.1016\/j.anai.2025.06.032_bib0003","doi-asserted-by":"crossref","first-page":"3250","DOI":"10.1016\/j.jaip.2024.08.044","article-title":"Harmonization of diagnostic criteria in mastocytosis for use in clinical practice: WHO vs ICC vs AIM\/ECNM","volume":"12","author":"Valent","year":"2024","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"8","key":"10.1016\/j.anai.2025.06.032_bib0004","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1016\/j.jaip.2022.05.007","article-title":"Global classification of mast cell activation disorders: an ICD-10-CM-adjusted proposal of the ECNM-AIM consortium","volume":"10","author":"Valent","year":"2022","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"2D","key":"10.1016\/j.anai.2025.06.032_bib0005","doi-asserted-by":"crossref","DOI":"10.6004\/jnccn.2024.0030","article-title":"NCCN guidelines \u00ae insights: systemic mastocytosis. version 3.2024","volume":"22","author":"Gotlib","year":"2024","journal-title":"J Natl Compr Canc Netw"},{"issue":"6","key":"10.1016\/j.anai.2025.06.032_bib0006","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1016\/j.jaci.2010.08.035","article-title":"Mast cell activation syndrome: proposed diagnostic criteria","volume":"126","author":"Akin","year":"2010","journal-title":"J Allergy Clin Immunol"},{"issue":"2","key":"10.1016\/j.anai.2025.06.032_bib0007","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1056\/NEJMra1409760","article-title":"Mast Cells, Mastocytosis, and related disorders","volume":"373","author":"Theoharides","year":"2015","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.anai.2025.06.032_bib0008","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.iac.2014.01.009","article-title":"Molecular defects in mastocytosis: KIT and beyond KIT","volume":"34","author":"Bibi","year":"2014","journal-title":"Immunol Allergy Clin North Am"},{"issue":"1","key":"10.1016\/j.anai.2025.06.032_bib0009","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.jaci.2015.08.034","article-title":"Cutaneous manifestations in patients with mastocytosis: consensus report of the European Competence Network on Mastocytosis; the American Academy of Allergy, Asthma & Immunology; and the European Academy of Allergology and Clinical Immunology","volume":"137","author":"Hartmann","year":"2016","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"10.1016\/j.anai.2025.06.032_bib0010","doi-asserted-by":"crossref","first-page":"42","DOI":"10.2174\/1573396315666181120163952","article-title":"Childhood solitary cutaneous mastocytoma: clinical manifestations, diagnosis, evaluation, and management","volume":"15","author":"Leung","year":"2019","journal-title":"Curr Pediatr Rev"},{"issue":"5","key":"10.1016\/j.anai.2025.06.032_bib0011","doi-asserted-by":"crossref","first-page":"2684","DOI":"10.3390\/ijms22052684","article-title":"Mediator-related symptoms and anaphylaxis in children with mastocytosis","volume":"22","author":"Brockow","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"4","key":"10.1016\/j.anai.2025.06.032_bib0012","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1089\/ped.2013.0275","article-title":"Pediatric mastocytosis: a review of the literature","volume":"26","author":"Frieri","year":"2013","journal-title":"Pediatr Allergy Immunol Pulmonol"},{"issue":"7","key":"10.1016\/j.anai.2025.06.032_bib0013","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1016\/j.jid.2020.12.030","article-title":"Clinical impact of skin lesions in mastocytosis: a multicenter study of the European competence network on mastocytosis","volume":"141","author":"Aberer","year":"2021","journal-title":"J Invest Dermatol"},{"issue":"5","key":"10.1016\/j.anai.2025.06.032_bib0014","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1136\/adc.86.5.315","article-title":"Paediatric mastocytosis","volume":"86","author":"Carter","year":"2002","journal-title":"Arch Dis Child"},{"issue":"6","key":"10.1016\/j.anai.2025.06.032_bib0015","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1111\/j.1365-2362.2007.01807.x","article-title":"Standards and standardization in mastocytosis: consensus statements on diagnostics, treatment recommendations and response criteria","volume":"37","author":"Valent","year":"2007","journal-title":"Eur J Clin Invest"},{"issue":"11","key":"10.1016\/j.anai.2025.06.032_bib0016","doi-asserted-by":"crossref","first-page":"e646","DOI":"10.1097\/HS9.0000000000000646","article-title":"Updated diagnostic criteria and classification of mast cell disorders: a consensus proposal","volume":"5","author":"Valent","year":"2021","journal-title":"Hemasphere"},{"issue":"6","key":"10.1016\/j.anai.2025.06.032_bib0017","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1158\/0008-5472.CAN-16-2234","article-title":"Advances in the classification and treatment of mastocytosis: current status and outlook toward the future","volume":"77","author":"Valent","year":"2017","journal-title":"Cancer Res"},{"issue":"7","key":"10.1016\/j.anai.2025.06.032_bib0018","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","article-title":"The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic\/dendritic neoplasms","volume":"36","author":"Khoury","year":"2022","journal-title":"Leukemia"},{"issue":"11","key":"10.1016\/j.anai.2025.06.032_bib0019","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1182\/blood.2022015850","article-title":"International Consensus Classification of Myeloid neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data","volume":"140","author":"Arber","year":"2022","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.anai.2025.06.032_bib0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.modpat.2023.100397","article-title":"Fifth edition of the World Health Classification of tumors of the hematopoietic and lymphoid tissue: myeloid neoplasms","volume":"37","author":"Loghavi","year":"2024","journal-title":"Mod Pathol"},{"issue":"8","key":"10.1016\/j.anai.2025.06.032_bib0021","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1002\/ajh.26966","article-title":"The international consensus classification of eosinophilic disorders and systemic mastocytosis","volume":"98","author":"Wang","year":"2023","journal-title":"Am J Hematol"},{"issue":"1","key":"10.1016\/j.anai.2025.06.032_bib0022","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1182\/hematology.2022000366","article-title":"How to evaluate the patient with a suspected mast cell disorder and how\/when to manage symptoms","volume":"2022","author":"Akin","year":"2022","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"6","key":"10.1016\/j.anai.2025.06.032_bib0023","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1016\/j.jaci.2010.02.019","article-title":"Clinical, biological, and molecular characteristics of clonal mast cell disorders presenting with systemic mast cell activation symptoms","volume":"125","author":"Alvarez-Twose","year":"2010","journal-title":"J Allergy Clin Immunol"},{"issue":"10","key":"10.1016\/j.anai.2025.06.032_bib0024","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1111\/j.1365-2222.2007.02804.x","article-title":"Prevalence of allergy and anaphylactic symptoms in 210 adult and pediatric patients with mastocytosis in Spain: a study of the Spanish network on mastocytosis (REMA)","volume":"37","author":"Gonz\u00e1lez de Olano","year":"2007","journal-title":"Clin Exp Allergy"},{"issue":"1","key":"10.1016\/j.anai.2025.06.032_bib0025","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.jaci.2017.05.036","article-title":"A distinct biomolecular profile identifies monoclonal mast cell disorders in patients with idiopathic anaphylaxis","volume":"141","author":"Carter","year":"2018","journal-title":"J Allergy Clin Immunol"},{"issue":"3","key":"10.1016\/j.anai.2025.06.032_bib0026","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1159\/000329856","article-title":"Validation of the REMA score for predicting mast cell clonality and systemic mastocytosis in patients with systemic mast cell activation symptoms","volume":"157","author":"Alvarez-Twose","year":"2012","journal-title":"Int Arch Allergy Immunol"},{"issue":"9","key":"10.1016\/j.anai.2025.06.032_bib0027","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1111\/cea.12369","article-title":"The presence of mast cell clonality in patients with unexplained anaphylaxis","volume":"44","author":"G\u00fclen","year":"2014","journal-title":"Clin Exp Allergy"},{"issue":"7","key":"10.1016\/j.anai.2025.06.032_bib0028","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1016\/j.jaip.2023.05.012","article-title":"Disease spectrum of anaphylaxis disorders","volume":"11","author":"Gonzalez de Olano","year":"2023","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"5","key":"10.1016\/j.anai.2025.06.032_bib0029","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1111\/bjh.15624","article-title":"Detection of KIT D816V in peripheral blood of children with manifestations of cutaneous mastocytosis suggests systemic disease","volume":"183","author":"Carter","year":"2018","journal-title":"Br J Haematol"},{"key":"10.1016\/j.anai.2025.06.032_bib0030","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1146\/annurev-pathmechdis-031521-042618","article-title":"New insights into the pathogenesis of mastocytosis: emerging concepts in diagnosis and therapy","volume":"18","author":"Valent","year":"2023","journal-title":"Annu Rev Pathol"},{"issue":"1","key":"10.1016\/j.anai.2025.06.032_bib0031","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1111\/j.1600-0609.2012.01789.x","article-title":"Circulating KIT D816V mutation-positive non-mast cells in peripheral blood are characteristic of indolent systemic mastocytosis","volume":"89","author":"Kristensen","year":"2012","journal-title":"Eur J Haematol"},{"issue":"6","key":"10.1016\/j.anai.2025.06.032_bib0032","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1111\/all.14165","article-title":"Clinical validation of a new commercial highly sensitive KIT D816V mutation analysis in mastocytosis","volume":"75","author":"Kristensen","year":"2020","journal-title":"Allergy"},{"issue":"9","key":"10.1016\/j.anai.2025.06.032_bib0033","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1182\/bloodadvances.2022007936","article-title":"Genetically defined individual reference ranges for tryptase limit unnecessary procedures and unmask myeloid neoplasms","volume":"7","author":"Chovanec","year":"2023","journal-title":"Blood Adv"},{"issue":"8","key":"10.1016\/j.anai.2025.06.032_bib0034","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1016\/j.jaip.2022.03.001","article-title":"Standards of genetic testing in the diagnosis and prognostication of systemic mastocytosis in 2022: recommendations of the EU-US Cooperative Group","volume":"10","author":"Hoermann","year":"2022","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"2","key":"10.1016\/j.anai.2025.06.032_bib0035","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1111\/j.1398-9995.2007.01569.x","article-title":"Anaphylaxis in patients with mastocytosis: a study on history, clinical features and risk factors in 120 patients","volume":"63","author":"Brockow","year":"2008","journal-title":"Allergy"},{"issue":"2","key":"10.1016\/j.anai.2025.06.032_bib0036","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.jaip.2024.10.039","article-title":"Demographics, types of patient-reported allergic diseases, and anaphylaxis in mastocytosis: a single-center US experience","volume":"13","author":"Kaakati","year":"2025","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"9","key":"10.1016\/j.anai.2025.06.032_bib0037","doi-asserted-by":"crossref","first-page":"2470","DOI":"10.1111\/all.16132","article-title":"Prevalence of hypersensitivity reactions in various forms of mastocytosis: a pilot study of 2485 adult patients with mastocytosis collected in the ECNM registry","volume":"79","author":"Niedoszytko","year":"2024","journal-title":"Allergy"},{"issue":"2","key":"10.1016\/j.anai.2025.06.032_bib0038","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/j.jaci.2012.10.052","article-title":"Systemic mastocytosis as a risk factor for severe Hymenoptera sting-induced anaphylaxis","volume":"131","author":"Alvarez-Twose","year":"2013","journal-title":"J Allergy Clin Immunol"},{"issue":"7","key":"10.1016\/j.anai.2025.06.032_bib0039","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1016\/j.jaip.2023.04.016","article-title":"Venom anaphylaxis: decision points for a more aggressive workup","volume":"11","author":"Bonadonna","year":"2023","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"3","key":"10.1016\/j.anai.2025.06.032_bib0040","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1016\/j.jaci.2008.11.018","article-title":"Clonal mast cell disorders in patients with systemic reactions to Hymenoptera stings and increased serum tryptase levels","volume":"123","author":"Bonadonna","year":"2009","journal-title":"J Allergy Clin Immunol"},{"issue":"3","key":"10.1016\/j.anai.2025.06.032_bib0041","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.jaip.2015.03.015","article-title":"Anaphylaxis after hymenoptera sting: is it venom allergy, a clonal disorder, or both?","volume":"3","author":"Castells","year":"2015","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"2","key":"10.1016\/j.anai.2025.06.032_bib0042","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/j.jaci.2021.02.043","article-title":"Routine KIT p.D816V screening identifies clonal mast cell disease in patients with Hymenoptera allergy regularly missed using baseline tryptase levels alone","volume":"148","author":"\u0160elb","year":"2021","journal-title":"J Allergy Clin Immunol"},{"issue":"12","key":"10.1016\/j.anai.2025.06.032_bib0043","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1038\/ng.3696","article-title":"Elevated basal serum tryptase identifies a multisystem disorder associated with increased TPSAB1 copy number","volume":"48","author":"Lyons","year":"2016","journal-title":"Nat Genet"},{"issue":"4","key":"10.1016\/j.anai.2025.06.032_bib0044","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/s11882-024-01136-y","article-title":"Alpha-tryptase as a risk-modifying factor for mast cell-mediated reactions","volume":"24","author":"Shin","year":"2024","journal-title":"Curr Allergy Asthma Rep"},{"issue":"2","key":"10.1016\/j.anai.2025.06.032_bib0045","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1016\/j.jaci.2021.06.017","article-title":"Hereditary alpha tryptasemia is not associated with specific clinical phenotypes","volume":"149","author":"Chollet","year":"2022","journal-title":"J Allergy Clin Immunol"},{"issue":"8","key":"10.1016\/j.anai.2025.06.032_bib0046","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1016\/j.jaip.2022.05.003","article-title":"Incorporating tryptase genotyping into the workup and diagnosis of mast cell diseases and reactions","volume":"10","author":"Lyons","year":"2022","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"9","key":"10.1016\/j.anai.2025.06.032_bib0047","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.1016\/j.jaip.2022.06.028","article-title":"Elevated tryptase: conditions and pitfalls","volume":"10","author":"Pongdee","year":"2022","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"2","key":"10.1016\/j.anai.2025.06.032_bib0048","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.jaci.2017.06.007","article-title":"Mast cell activation syndromes","volume":"140","author":"Akin","year":"2017","journal-title":"J Allergy Clin Immunol"},{"issue":"2","key":"10.1016\/j.anai.2025.06.032_bib0049","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s11882-024-01126-0","article-title":"Using the right criteria for MCAS","volume":"24","author":"Gulen","year":"2024","journal-title":"Curr Allergy Asthma Rep"},{"issue":"11","key":"10.1016\/j.anai.2025.06.032_bib0050","doi-asserted-by":"crossref","first-page":"3918","DOI":"10.1016\/j.jaip.2021.06.011","article-title":"Selecting the right criteria and proper classification to diagnose mast cell activation syndromes: a critical review","volume":"9","author":"G\u00fclen","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"26","key":"10.1016\/j.anai.2025.06.032_bib0051","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1056\/NEJM198706253162603","article-title":"Tryptase levels as an indicator of mast-cell activation in systemic anaphylaxis and mastocytosis","volume":"316","author":"Schwartz","year":"1987","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.anai.2025.06.032_bib0052","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1016\/j.jaip.2022.03.007","article-title":"Personalized management strategies in mast cell disorders: ECNM-AIM User\u2019s guide for daily clinical practice","volume":"10","author":"Valent","year":"2022","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"10","key":"10.1016\/j.anai.2025.06.032_bib0053","doi-asserted-by":"crossref","first-page":"3010","DOI":"10.1016\/j.jaip.2023.08.008","article-title":"The normal range of baseline tryptase should be 1 to 15 ng\/mL and covers healthy individuals with H\u03b1T","volume":"11","author":"Valent","year":"2023","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"1","key":"10.1016\/j.anai.2025.06.032_bib0054","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1159\/000501079","article-title":"Why the 20% + 2 tryptase formula is a diagnostic gold standard for severe systemic mast cell activation and mast cell activation syndrome","volume":"180","author":"Valent","year":"2019","journal-title":"Int Arch Allergy Immunol"},{"issue":"3","key":"10.1016\/j.anai.2025.06.032_bib0055","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1016\/j.jaci.2021.08.007","article-title":"Defining baseline variability of serum tryptase levels improves accuracy in identifying anaphylaxis","volume":"149","author":"Mateja","year":"2022","journal-title":"J Allergy Clin Immunol"},{"issue":"8","key":"10.1016\/j.anai.2025.06.032_bib0056","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.1016\/j.jaip.2022.03.008","article-title":"Nontryptase urinary and hematologic biomarkers of mast cell expansion and mast cell activation: status 2022","volume":"10","author":"Butterfield","year":"2022","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"8","key":"10.1016\/j.anai.2025.06.032_bib0057","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1016\/j.jaip.2023.02.017","article-title":"Increased excretion of mast cell mediator metabolites during mast cell activation syndrome","volume":"11","author":"Butterfield","year":"2023","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"4","key":"10.1016\/j.anai.2025.06.032_bib0058","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1016\/j.jaip.2019.02.002","article-title":"Mast cell activation syndrome and mastocytosis: initial treatment options and long-term management","volume":"7","author":"Castells","year":"2019","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"2","key":"10.1016\/j.anai.2025.06.032_bib0059","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1080\/17425247.2023.2166926","article-title":"Drug delivery targets and strategies to address mast cell diseases","volume":"20","author":"Rische","year":"2023","journal-title":"Expert Opin Drug Deliv"},{"issue":"1","key":"10.1016\/j.anai.2025.06.032_bib0060","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.jaci.2011.04.037","article-title":"Mast cell activation syndrome: a newly recognized disorder with systemic clinical manifestations","volume":"128","author":"Hamilton","year":"2011","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"10.1016\/j.anai.2025.06.032_bib0061","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1007\/s11882-012-0326-8","article-title":"Immunology and clinical manifestations of non-clonal mast cell activation syndrome","volume":"13","author":"Cardet","year":"2013","journal-title":"Curr Allergy Asthma Rep"},{"issue":"2","key":"10.1016\/j.anai.2025.06.032_bib0062","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.jaci.2024.05.025","article-title":"Mast cell activation syndrome: current understanding and research needs","volume":"154","author":"Castells","year":"2024","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"10.1016\/j.anai.2025.06.032_bib0063","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s11882-024-01183-5","article-title":"Mast cells and mas-related G protein-coupled receptor X2: itching for novel pathophysiological insights to clinical relevance","volume":"25","author":"Castells","year":"2025","journal-title":"Curr Allergy Asthma Rep"},{"key":"10.1016\/j.anai.2025.06.032_bib0064","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.930945","article-title":"The number of MRGPRX2-expressing cells is increased in skin lesions of patients with indolent systemic mastocytosis, but is not linked to symptom severity","volume":"13","author":"Pyatilova","year":"2022","journal-title":"Front Immunol"},{"issue":"10","key":"10.1016\/j.anai.2025.06.032_bib0065","doi-asserted-by":"crossref","first-page":"3233","DOI":"10.1111\/all.14891","article-title":"Medical algorithm: peri-operative management of mastocytosis patients","volume":"76","author":"Bocca-Tjeertes","year":"2021","journal-title":"Allergy"},{"issue":"3","key":"10.1016\/j.anai.2025.06.032_bib0066","doi-asserted-by":"crossref","DOI":"10.1002\/clt2.12132","article-title":"Mastocytosis presenting with mast cell-mediator release-associated symptoms elicited by cyclo oxygenase inhibitors: prevalence, clinical, and laboratory features","volume":"12","author":"Rama","year":"2022","journal-title":"Clin Transl Allergy"},{"issue":"9","key":"10.1016\/j.anai.2025.06.032_bib0067","doi-asserted-by":"crossref","first-page":"3093","DOI":"10.1016\/j.jaip.2020.05.044","article-title":"Low frequency of IgE-mediated food hypersensitivity in mastocytosis","volume":"8","author":"Jarkvist","year":"2020","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"7","key":"10.1016\/j.anai.2025.06.032_bib0068","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.1016\/j.jaip.2024.03.040","article-title":"Drug-induced anaphylaxis uncommon in mastocytosis: findings from two large cohorts","volume":"12","author":"Beyens","year":"2024","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"3","key":"10.1016\/j.anai.2025.06.032_bib0069","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.iac.2018.04.006","article-title":"Patient perceptions in mast cell disorders","volume":"38","author":"Jennings","year":"2018","journal-title":"Immunol Allergy Clin North Am"},{"issue":"24","key":"10.1016\/j.anai.2025.06.032_bib0070","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1056\/NEJM198012113032405","article-title":"Increased production of prostaglandin D2 in patients with systemic mastocytosis","volume":"303","author":"Roberts","year":"1980","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.anai.2025.06.032_bib0071","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.anai.2021.10.006","article-title":"Mast cell disorders are associated with decreased cerebral blood flow and small fiber neuropathy","volume":"128","author":"Novak","year":"2022","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"8","key":"10.1016\/j.anai.2025.06.032_bib0072","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1016\/j.jaip.2024.05.027","article-title":"Cumulative dose effects of H1 antihistamine use on the risk of dementia in patients with allergic rhinitis","volume":"12","author":"Su","year":"2024","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"7","key":"10.1016\/j.anai.2025.06.032_bib0073","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1159\/000524532","article-title":"Mast cell activation syndromes: Collegium Internationale Allergologicum update 2022","volume":"183","author":"Valent","year":"2022","journal-title":"Int Arch Allergy Immunol"},{"issue":"2","key":"10.1016\/j.anai.2025.06.032_bib0074","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1159\/000237133","article-title":"Cysteinyl leukotriene production in anaphylactic reactions","volume":"108","author":"Denzlinger","year":"1995","journal-title":"Int Arch Allergy Immunol"},{"issue":"2","key":"10.1016\/j.anai.2025.06.032_bib0075","article-title":"Acute\/baseline ratios of all 3 MC mediator metabolites can enhance diagnosis and management of mast cell activation syndrome","volume":"4","author":"Butterfield","year":"2025","journal-title":"J Allergy Clin Immunol Glob"},{"issue":"2","key":"10.1016\/j.anai.2025.06.032_bib0076","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1111\/1523-1747.ep12531738","article-title":"Local effects of synthetic leukotrienes (LTC4, LTD4, LTE4, and LTB4) in human skin","volume":"80","author":"Soter","year":"1983","journal-title":"J Invest Dermatol"},{"issue":"3","key":"10.1016\/j.anai.2025.06.032_bib0077","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1111\/j.1476-5381.1983.tb10721.x","article-title":"Responses of human skin to intradermal injection of leukotrienes C4, D4 and B4","volume":"80","author":"Camp","year":"1983","journal-title":"Br J Pharmacol"},{"issue":"25","key":"10.1016\/j.anai.2025.06.032_bib0078","doi-asserted-by":"crossref","first-page":"22608","DOI":"10.1074\/jbc.M103562200","article-title":"Attenuated zymosan-induced peritoneal vascular permeability and IgE-dependent passive cutaneous anaphylaxis in mice lacking leukotriene C4 synthase","volume":"276","author":"Kanaoka","year":"2001","journal-title":"J Biol Chem"},{"issue":"23","key":"10.1016\/j.anai.2025.06.032_bib0079","doi-asserted-by":"crossref","first-page":"20820","DOI":"10.1074\/jbc.M203163200","article-title":"Targeted gene disruption reveals the role of cysteinyl leukotriene 1 receptor in the enhanced vascular permeability of mice undergoing acute inflammatory responses","volume":"277","author":"Maekawa","year":"2002","journal-title":"J Biol Chem"},{"issue":"22","key":"10.1016\/j.anai.2025.06.032_bib0080","doi-asserted-by":"crossref","first-page":"11939","DOI":"10.1016\/S0021-9258(19)68496-6","article-title":"Tryptase from human pulmonary mast cells. Purification and characterization","volume":"256","author":"Schwartz","year":"1981","journal-title":"J Biol Chem"},{"issue":"6","key":"10.1016\/j.anai.2025.06.032_bib0081","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1097\/00006842-198607000-00006","article-title":"Mixed organic brain syndrome as a manifestation of systemic mastocytosis","volume":"48","author":"Rogers","year":"1986","journal-title":"Psychosom Med"},{"issue":"6","key":"10.1016\/j.anai.2025.06.032_bib0082","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/j.jaip.2014.06.011","article-title":"Mast cell activation syndrome: improved identification by combined determinations of serum tryptase and 24-hour urine 11\u03b2-Prostaglandin2\u03b1","volume":"2","author":"Ravi","year":"2014","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"9","key":"10.1016\/j.anai.2025.06.032_bib0083","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1056\/NEJM197908303010903","article-title":"Oral disodium cromoglycate in the treatment of systemic mastocytosis","volume":"301","author":"Soter","year":"1979","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.anai.2025.06.032_bib0084","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1056\/NEJMcpc1013929","article-title":"Case records of the Massachusetts General Hospital. Case 9-2011.A 37-year-old man with flushing and hypotension","volume":"364","author":"Murali","year":"2011","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.anai.2025.06.032_bib0085","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1111\/all.12617","article-title":"Drug hypersensitivity in clonal mast cell disorders: ENDA\/EAACI position paper","volume":"70","author":"Bonadonna","year":"2015","journal-title":"Allergy"},{"issue":"3-4","key":"10.1016\/j.anai.2025.06.032_bib0086","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.prostaglandins.2009.01.001","article-title":"Survey of aspirin administration in systemic mastocytosis","volume":"88","author":"Butterfield","year":"2009","journal-title":"Prostaglandins Other Lipid Mediat"},{"issue":"2","key":"10.1016\/j.anai.2025.06.032_bib0087","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.anai.2023.09.015","article-title":"Anaphylaxis: a 2023 practice parameter update","volume":"132","author":"Golden","year":"2024","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"6","key":"10.1016\/j.anai.2025.06.032_bib0088","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1111\/cea.13592","article-title":"Omalizumab in the treatment of adult patients with mastocytosis: a systematic review","volume":"50","author":"Jendoubi","year":"2020","journal-title":"Clin Exp Allergy"},{"issue":"6","key":"10.1016\/j.anai.2025.06.032_bib0089","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1016\/j.jaci.2007.03.032","article-title":"Omalizumab for the treatment of unprovoked anaphylaxis in patients with systemic mastocytosis","volume":"119","author":"Carter","year":"2007","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.anai.2025.06.032_bib0090","article-title":"Efficacy of omalizumab in indolent systemic mastocytosis","volume":"2019","author":"Slapnicar","year":"2019","journal-title":"Case Rep Hematol"},{"issue":"1","key":"10.1016\/j.anai.2025.06.032_bib0091","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.jaci.2024.11.004","article-title":"Omalizumab for mast cell disorders","volume":"155","author":"Akin","year":"2025","journal-title":"J Allergy Clin Immunol"},{"issue":"4","key":"10.1016\/j.anai.2025.06.032_bib0092","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1016\/j.jaip.2019.10.022","article-title":"One-day ultrarush desensitization for Hymenoptera venom anaphylaxis in patients with and without mast cell disorders with adjuvant omalizumab","volume":"8","author":"Giannetti","year":"2020","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"10","key":"10.1016\/j.anai.2025.06.032_bib0093","doi-asserted-by":"crossref","DOI":"10.1002\/cti2.1075","article-title":"Successful treatment of idiopathic mast cell activation syndrome with low-dose omalizumab","volume":"8","author":"Berry","year":"2019","journal-title":"Clin Transl Immunology"},{"issue":"7","key":"10.1016\/j.anai.2025.06.032_bib0094","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1016\/j.jaip.2019.03.039","article-title":"Omalizumab therapy for mast cell-mediator symptoms in patients with ISM, CM, MMAS, and MCAS","volume":"7","author":"Lemal","year":"2019","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"8","key":"10.1016\/j.anai.2025.06.032_bib0095","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1111\/all.14248","article-title":"Clinical features and survival of patients with indolent systemic mastocytosis defined by the updated WHO classification","volume":"75","author":"Trizuljak","year":"2020","journal-title":"Allergy"},{"issue":"10","key":"10.1016\/j.anai.2025.06.032_bib0096","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1111\/all.12668","article-title":"Urinary 11\u03b2-PGF2\u03b1 and N-methyl histamine correlate with bone marrow biopsy findings in mast cell disorders","volume":"70","author":"Divekar","year":"2015","journal-title":"Allergy"},{"issue":"10","key":"10.1016\/j.anai.2025.06.032_bib0097","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0076116","article-title":"Serum tryptase monitoring in indolent systemic mastocytosis: association with disease features and patient outcome","volume":"8","author":"Matito","year":"2013","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.anai.2025.06.032_bib0098","doi-asserted-by":"crossref","first-page":"2160","DOI":"10.1016\/j.jaip.2021.04.023","article-title":"Triggers of exacerbation in chronic urticaria and recurrent angioedema-prevalence and relevance","volume":"9","author":"Grumach","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"10","key":"10.1016\/j.anai.2025.06.032_bib0099","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1111\/all.13445","article-title":"Low frequency of acetyl salicylic acid hypersensitivity in mastocytosis: the results of a double-blind, placebo-controlled challenge study","volume":"73","author":"Hermans","year":"2018","journal-title":"Allergy"},{"issue":"6","key":"10.1016\/j.anai.2025.06.032_bib0100","doi-asserted-by":"crossref","first-page":"428","DOI":"10.4103\/2229-5178.169731","article-title":"Aspirin in dermatology: revisited","volume":"6","author":"Bubna","year":"2015","journal-title":"Indian Dermatol Online J"},{"issue":"8A","key":"10.1016\/j.anai.2025.06.032_bib0101","doi-asserted-by":"crossref","first-page":"14B","DOI":"10.1016\/j.amjcard.2008.02.028","article-title":"Niacin use and cutaneous flushing: mechanisms and strategies for prevention","volume":"101","author":"Davidson","year":"2008","journal-title":"Am J Cardiol"},{"issue":"3","key":"10.1016\/j.anai.2025.06.032_bib0102","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1111\/j.1468-3083.1999.tb00878.x","article-title":"Mastocytosis with skin manifestations: current status","volume":"13","author":"Katsambas","year":"1999","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"5-6","key":"10.1016\/j.anai.2025.06.032_bib0103","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1111\/phpp.12248","article-title":"Narrow-band UVB phototherapy and psoralen-ultraviolet A photochemotherapy in the treatment of cutaneous mastocytosis: a study in 20 patients","volume":"32","author":"Brazzelli","year":"2016","journal-title":"Photodermatol Photoimmunol Photomed"},{"issue":"1","key":"10.1016\/j.anai.2025.06.032_bib0104","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1111\/all.13237","article-title":"Omalizumab prevents anaphylaxis and improves symptoms in systemic mastocytosis: efficacy and safety observations","volume":"73","author":"Broesby-Olsen","year":"2018","journal-title":"Allergy"},{"issue":"12","key":"10.1016\/j.anai.2025.06.032_bib0105","doi-asserted-by":"crossref","first-page":"4459","DOI":"10.1016\/j.jaip.2021.08.001","article-title":"Assessment of osteoporosis and fracture risk in mastocytosis within a North American cohort","volume":"9","author":"Makovoz","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.anai.2025.06.032_bib0106","doi-asserted-by":"crossref","DOI":"10.1016\/j.bone.2024.117141","article-title":"Underlying systemic mastocytosis in patients with unexplained osteoporosis: score proposal","volume":"186","author":"Tanasi","year":"2024","journal-title":"Bone"},{"issue":"3","key":"10.1016\/j.anai.2025.06.032_bib0107","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1093\/rheumatology\/36.3.393","article-title":"The effect of pamidronate on lumbar spine bone density and pain in osteoporosis secondary to systemic mastocytosis","volume":"36","author":"Marshall","year":"1997","journal-title":"Br J Rheumatol"},{"issue":"1","key":"10.1016\/j.anai.2025.06.032_bib0108","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1007\/s00223-016-0198-3","article-title":"Longitudinal evaluation of bone mineral density and bone metabolism markers in patients with indolent systemic mastocytosis without osteoporosis","volume":"100","author":"Artuso","year":"2017","journal-title":"Calcif Tissue Int"},{"issue":"6","key":"10.1016\/j.anai.2025.06.032_bib0109","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1007\/s00223-021-00887-4","article-title":"Osteoporosis caused by systemic mastocytosis: prevalence in a cohort of 8392 patients with osteoporosis","volume":"109","author":"Gehlen","year":"2021","journal-title":"Calcif Tissue Int"},{"issue":"8","key":"10.1016\/j.anai.2025.06.032_bib0110","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1007\/s00198-016-3539-1","article-title":"Prevalence, pathogenesis, and treatment options for mastocytosis-related osteoporosis","volume":"27","author":"Rossini","year":"2016","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.anai.2025.06.032_bib0111","first-page":"22","article-title":"Skin and bones: systemic mastocytosis and bone","volume":"2023","author":"Wang","year":"2023","journal-title":"Endocrinol Diabetes Metab Case Rep"},{"issue":"6","key":"10.1016\/j.anai.2025.06.032_bib0112","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1136\/ard.2004.029116","article-title":"Systemic mastocytosis: a rare cause of osteoporosis and its response to bisphosphonate treatment","volume":"64","author":"Lim","year":"2005","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"10.1016\/j.anai.2025.06.032_bib0113","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1007\/s00223-017-0241-z","article-title":"Denosumab for the treatment of mastocytosis-related osteoporosis: a case series","volume":"100","author":"Orsolini","year":"2017","journal-title":"Calcif Tissue Int"},{"issue":"11","key":"10.1016\/j.anai.2025.06.032_bib0114","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1002\/jbmr.5650051104","article-title":"Inhibition of mediator release in systemic mastocytosis is associated with reversal of bone changes","volume":"5","author":"Graves","year":"1990","journal-title":"J Bone Miner Res"},{"issue":"4","key":"10.1016\/j.anai.2025.06.032_bib0115","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1016\/0091-6749(90)90205-I","article-title":"Ketotifen and systemic mastocytosis","volume":"85","author":"Ting","year":"1990","journal-title":"J Allergy Clin Immunol"},{"issue":"2","key":"10.1016\/j.anai.2025.06.032_bib0116","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.jaci.2007.11.010","article-title":"Safety and effectiveness of immunotherapy in patients with indolent systemic mastocytosis presenting with Hymenoptera venom anaphylaxis","volume":"121","author":"de Olano","year":"2008","journal-title":"J Allergy Clin Immunol"},{"issue":"2","key":"10.1016\/j.anai.2025.06.032_bib0117","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/0091-6749(83)90098-2","article-title":"Robertsii LJ 2nd. Intervention with epinephrine in hypotension associated with mastocytosis","volume":"71","author":"Turk","year":"1983","journal-title":"J Allergy Clin Immunol"},{"issue":"9","key":"10.1016\/j.anai.2025.06.032_bib0118","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1016\/j.jaip.2024.06.036","article-title":"Anaphylaxis in practice: a guide to the 2023 practice parameter update","volume":"12","author":"Wang","year":"2024","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"4","key":"10.1016\/j.anai.2025.06.032_bib0119","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1007\/s40265-020-01275-2","article-title":"Avapritinib: first approval","volume":"80","author":"Dhillon","year":"2020","journal-title":"Drugs"},{"key":"10.1016\/j.anai.2025.06.032_bib0120","unstructured":"Food and Drug Administration. Avapritinib package insert. Accessed July 21, 2025. Available at: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/212608s000lbl.pdf"},{"issue":"2","key":"10.1016\/j.anai.2025.06.032_bib0121","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1158\/2159-8290.CD-NB2017-177","article-title":"Rapid responses to avapritinib (BLU-285) in mastocytosis","volume":"8","year":"2018","journal-title":"Cancer Discov"},{"issue":"12","key":"10.1016\/j.anai.2025.06.032_bib0122","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1038\/s41591-021-01538-9","article-title":"Safety and efficacy of avapritinib in advanced systemic mastocytosis: the phase 1 EXPLORER trial","volume":"27","author":"DeAngelo","year":"2021","journal-title":"Nat Med"},{"issue":"6","key":"10.1016\/j.anai.2025.06.032_bib0123","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2200339","article-title":"Avapritinib versus Placebo in Indolent Systemic mastocytosis","volume":"2","author":"Gotlib","year":"2023","journal-title":"NEJM Evid"},{"issue":"12","key":"10.1016\/j.anai.2025.06.032_bib0124","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1634\/theoncologist.2018-0222","article-title":"FDA approval summary: midostaurin for the treatment of advanced systemic mastocytosis","volume":"23","author":"Kasamon","year":"2018","journal-title":"Oncologist"},{"issue":"3","key":"10.1016\/j.anai.2025.06.032_bib0125","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1016\/j.jaci.2018.06.003","article-title":"Midostaurin in patients with indolent systemic mastocytosis: an open-label phase 2 trial","volume":"142","author":"van Anrooij","year":"2018","journal-title":"J Allergy Clin Immunol"},{"issue":"4","key":"10.1016\/j.anai.2025.06.032_bib0126","doi-asserted-by":"crossref","first-page":"E138","DOI":"10.1002\/ajh.26464","article-title":"Midostaurin therapy for indolent and smoldering systemic mastocytosis: retrospective review of Mayo Clinic experience","volume":"97","author":"Farrukh","year":"2022","journal-title":"Am J Hematol"},{"issue":"5","key":"10.1016\/j.anai.2025.06.032_bib0127","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1038\/sj.onc.1206120","article-title":"Effect of tyrosine kinase inhibitor STI571 on the kinase activity of wild-type and various mutated c-kit receptors found in mast cell neoplasms","volume":"22","author":"Zermati","year":"2003","journal-title":"Oncogene"},{"issue":"5","key":"10.1016\/j.anai.2025.06.032_bib0128","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1182\/blood.V99.5.1741","article-title":"The c-KIT mutation causing human mastocytosis is resistant to STI571 and other KIT kinase inhibitors; kinases with enzymatic site mutations show different inhibitor sensitivity profiles than wild-type kinases and those with regulatory-type mutations","volume":"99","author":"Ma","year":"2002","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.anai.2025.06.032_bib0129","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/S0301-472X(03)00112-7","article-title":"Effects of tyrosine kinase inhibitor STI571 on human mast cells bearing wild-type or mutated c-kit","volume":"31","author":"Akin","year":"2003","journal-title":"Exp Hematol"},{"issue":"2","key":"10.1016\/j.anai.2025.06.032_bib0130","first-page":"93","article-title":"Long-lasting complete response to imatinib in a patient with systemic mastocytosis exhibiting wild type KIT","volume":"4","author":"Valent","year":"2014","journal-title":"Am J Blood Res"},{"issue":"2","key":"10.1016\/j.anai.2025.06.032_bib0131","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1002\/cncr.21996","article-title":"Imatinib mesylate in the treatment of systemic mastocytosis: a phase II trial","volume":"107","author":"Droogendijk","year":"2006","journal-title":"Cancer"},{"issue":"11","key":"10.1016\/j.anai.2025.06.032_bib0132","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1016\/j.leukres.2008.12.020","article-title":"Phase II study of imatinib mesylate as therapy for patients with systemic mastocytosis","volume":"33","author":"Vega-Ruiz","year":"2009","journal-title":"Leuk Res"},{"issue":"12","key":"10.1016\/j.anai.2025.06.032_bib0133","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1002\/ajh.21561","article-title":"Cytoreductive therapy in 108 adults with systemic mastocytosis: outcome analysis and response prediction during treatment with interferon-alpha, hydroxyurea, imatinib mesylate or 2-chlorodeoxyadenosine","volume":"84","author":"Lim","year":"2009","journal-title":"Am J Hematol"},{"issue":"8","key":"10.1016\/j.anai.2025.06.032_bib0134","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1182\/blood-2014-12-614743","article-title":"Long-term efficacy and safety of cladribine (2-CdA) in adult patients with mastocytosis","volume":"126","author":"Barete","year":"2015","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.anai.2025.06.032_bib0135","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1056\/NEJM199202273260907","article-title":"Response to interferon alfa-2b in a patient with systemic mastocytosis","volume":"326","author":"Kluin-Nelemans","year":"1992","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.anai.2025.06.032_bib0136","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.patbio.2004.04.012","article-title":"Interest of interferon alpha in systemic mastocytosis. The French experience and review of the literature","volume":"52","author":"Simon","year":"2004","journal-title":"Pathol Biol (Paris)"},{"issue":"6","key":"10.1016\/j.anai.2025.06.032_bib0137","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1111\/j.1365-2796.1997.tb00013.x","article-title":"Clinical stable systemic mastocytosis with interferon alpha-2b therapy","volume":"241","author":"H\u00fcbner","year":"1997","journal-title":"J Intern Med"},{"issue":"2","key":"10.1016\/j.anai.2025.06.032_bib0138","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.leukres.2004.05.003","article-title":"Successful treatment of systemic mastocytosis with high-dose interferon-alfa: long-term follow-up of a case","volume":"29","author":"Butterfield","year":"2005","journal-title":"Leuk Res"},{"issue":"5-6","key":"10.1016\/j.anai.2025.06.032_bib0139","doi-asserted-by":"crossref","first-page":"501","DOI":"10.3109\/10428199609054789","article-title":"Treatment of three patients with systemic mastocytosis with interferon alpha-2b","volume":"22","author":"Worobec","year":"1996","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.anai.2025.06.032_bib0140","unstructured":"Food and Drug Administration. Dasatinib package insert. Accessed July 21, 2025. Available at: www.accessdata.fda.gov\/drugsatfda_docs\/label\/2010\/021986s7s8lbl.pdf"},{"issue":"1","key":"10.1016\/j.anai.2025.06.032_bib0141","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1158\/0008-5472.CAN-05-2050","article-title":"Dasatinib (BMS-354825), a dual SRC\/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies","volume":"66","author":"Schittenhelm","year":"2006","journal-title":"Cancer Res"},{"issue":"5","key":"10.1016\/j.anai.2025.06.032_bib0142","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1111\/j.1600-0609.2008.01048.x","article-title":"Dasatinib therapy for systemic mastocytosis: four cases","volume":"80","author":"Purtill","year":"2008","journal-title":"Eur J Haematol"},{"issue":"12","key":"10.1016\/j.anai.2025.06.032_bib0143","doi-asserted-by":"crossref","first-page":"3906","DOI":"10.1158\/1078-0432.CCR-08-0366","article-title":"Phase II study of dasatinib in Philadelphia chromosome\u2013negative acute and chronic myeloid diseases, including systemic mastocytosis","volume":"14","author":"Verstovsek","year":"2008","journal-title":"Clin Cancer Res"},{"issue":"5","key":"10.1016\/j.anai.2025.06.032_bib0144","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1016\/j.jaci.2022.04.025","article-title":"Castells M. Differential mast cell mediators in systemic mastocytosis and hereditary \u03b1-tryptasemia","volume":"150","author":"Giannetti","year":"2022","journal-title":"J Allergy Clin Immunol"},{"issue":"3","key":"10.1016\/j.anai.2025.06.032_bib0145","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1111\/all.15911","article-title":"Clinical impact of the TPSAB1 genotype in mast cell diseases: a REMA study in a cohort of 959 individuals","volume":"79","author":"Gonzalez-de-Olano","year":"2024","journal-title":"Allergy"},{"issue":"2","key":"10.1016\/j.anai.2025.06.032_bib0146","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1016\/j.jaci.2020.06.035","article-title":"Heritable risk for severe anaphylaxis associated with increased \u03b1-tryptase-encoding germline copy number at TPSAB1","volume":"147","author":"Lyons","year":"2021","journal-title":"J Allergy Clin Immunol"},{"issue":"10","key":"10.1016\/j.anai.2025.06.032_bib0147","doi-asserted-by":"crossref","first-page":"2348","DOI":"10.1084\/jem.20190701","article-title":"Impact of naturally forming human \u03b1\/\u03b2-tryptase heterotetramers in the pathogenesis of hereditary \u03b1-tryptasemia","volume":"216","author":"Le","year":"2019","journal-title":"J Exp Med"},{"issue":"1","key":"10.1016\/j.anai.2025.06.032_bib0148","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.jaci.2014.11.035","article-title":"Clonal mast cell disorders in patients with severe Hymenoptera venom allergy and normal serum tryptase levels","volume":"136","author":"Zanotti","year":"2015","journal-title":"J Allergy Clin Immunol"},{"issue":"5","key":"10.1016\/j.anai.2025.06.032_bib0149","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1097\/ACI.0000000000000678","article-title":"Hymenoptera venom-induced anaphylaxis and hereditary alpha-tryptasemia","volume":"20","author":"O\u2019Connell","year":"2020","journal-title":"Curr Opin Allergy Clin Immunol"},{"issue":"9","key":"10.1016\/j.anai.2025.06.032_bib0150","doi-asserted-by":"crossref","first-page":"2458","DOI":"10.1111\/all.16084","article-title":"High burden of clonal mast cell disorders and hereditary \u03b1-tryptasemia in patients who need Hymenoptera venom immunotherapy","volume":"79","author":"Koro\u0161ec","year":"2024","journal-title":"Allergy"},{"issue":"2","key":"10.1016\/j.anai.2025.06.032_bib0151","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1001\/jama.1989.03430020082033","article-title":"Epidemiology of insect venom sensitivity","volume":"262","author":"Golden","year":"1989","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.anai.2025.06.032_bib0152","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.jaci.2019.05.007","article-title":"GATA-2-deficient mast cells limit IgE-mediated immediate hypersensitivity reactions in human subjects","volume":"144","author":"Desai","year":"2019","journal-title":"J Allergy Clin Immunol"},{"issue":"4","key":"10.1016\/j.anai.2025.06.032_bib0153","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.anai.2023.04.011","article-title":"A review of food allergy panels and their consequences","volume":"131","author":"Parrish","year":"2023","journal-title":"Ann Allergy Asthma Immunol"}],"container-title":["Annals of Allergy, Asthma & Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1081120625003369?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1081120625003369?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T06:14:08Z","timestamp":1759299248000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1081120625003369"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":153,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["S1081120625003369"],"URL":"https:\/\/doi.org\/10.1016\/j.anai.2025.06.032","relation":{},"ISSN":["1081-1206"],"issn-type":[{"value":"1081-1206","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Management of indolent mastocytosis and mast cell activation syndrome","name":"articletitle","label":"Article Title"},{"value":"Annals of Allergy, Asthma & Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.anai.2025.06.032","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 American College of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}